Don't Heed the Dramatic Market Call<br />By Rev Shark<br />RealMoney.com Contributor<br />10/22/2009 8:48 AM EDT <br /><br />Half of life is luck; the other half is discipline -- and that's the important half, for without discipline you wouldn't know what to do with luck. --Carl Zuckmeyer<br /><br />Since the market bottomed back in March, we have had five meaningful pullbacks. The most severe was in June and July prior to second-quarter earnings, but each time it looked like we were about to see a major change in trend, we recovered with great vigor. <br /><br />What has been most interesting about the action is how panic-buying set in once the indices found support and began to recover. Time and again, we have seen V-shaped recoveries as folks scrambled to reposition out of fear they will once again be left behind as the market continues to march higher. <br /><br />The lesson here is a pretty simple one: Be very slow to assume that the trend is ending and the character of the market is changing. <br /><br />One of the favorite games on Wall Street is the big, dramatic market call. Predictions that the trend is about to change garner lots of attention and allow market pundits to pontificate over weighty matters that they have been carefully contemplating. The problem is that getting the timing right is most often just a matter of luck. <br /><br />Market players are usually better off just sticking with the trend and using good money-management discipline to move them in and out of the market. In other words, don't sell your stocks because of market predictions. Sell them because they are acting poorly and have reached a logical place for you to cut losses or lock in gains. Action in the individual stocks you own should be your guide to exiting the market. <br /><br />One of the major benefits of focusing on individual stocks rather than major market calls is that it allows you to better handle the sector rotations that are always taking place. There are always going to be some sectors doing well while others struggle, and if you focus too much on the big market calls, you will miss out on those nuances. <br /><br />After the late selloff yesterday, we should start hearing more predictions about how the market is finally going to start the long-awaited correction. The bears have been battered and bewildered lately, but a couple of days of weakness and focus on the "sell the news" tendency so far this earnings season will likely stir up a little confidence again. <br /><br />It is indeed possible that a major trend change is about to occur, but I see no benefit at all in making such predictions. Just make sure you are using stops and have a disciplined approach to selling stocks that begin to struggle. Should a severe correction be at hand, you don't need to predict it in order to be safe. <br /><br />We have a little bounce brewing this morning as more strong earnings reports roll in. Good earnings have not been a lasting positive catalyst lately, so I'd be slow to chase the open. <br />-----------------------------<br />Ülespoole avanevad:<br /><br />In reaction to strong earnings/guidance: FFIV +10.5% (also upgraded to Buy from Hold at Canaccord Adams), JCG +10.3% (also initiated with a Buy at Jesup & Lamont), LOGI +8.7%, ALXN +7.1% (light volume), RODM +7.0%, BBX +6.5%, COHU +5.7%, AKNS +4.5% (light volume), TRV +4.1%, PNC +3.8%, XRX +3.6%, LZ +3.2%, T +2.9%, ZMH +2.8%, VMW +2.0%, NVLS +1.8% (also upgraded to Hold at Deutsche), MCD +1.8%, AMP +1.6%... M&A news: HTE +33.6% (Harvest Energy Trust agrees to C$4.1 bln sale to Korea National Oil; upgraded to Buy from Neutral at UBS and upgraded to Sector Perform from Underperform at RBC Capital Mkts), SDXC +21.5% (Switch & Data to be acquired by Equinix for either 0.19409 shares of Equinix stock or $19.06)... Other news: RNN +11.6% (new animal study supports Rexahn's Archexin as potent inhibitor of human cancer cell growth), KOG +7.7% (provided an interim update on its Williston Basin drilling and completion activities), ISIS +3.2% (reports positive Phase 2 data for ISIS 113715 in patients with Type 2 diabetes), SLM +2.9% (Cramer makes positive comments on MadMoney), LDK +2.7% (announces a supply contract with Enfinity), HCBK +0.9% (Cramer makes positive comments on MadMoney)... Analyst comments: LNN +4.3% (upgraded to Outperform at William Blair), MOT +1.7% (upgraded to Overweight at Weisel). <br /><br />Allapoole avanevad:<br /><br />In reaction to disappointing earnings/guidance: TQNT -19.8%, TEX -10.1%, NCR -10.0%, MJN -8.4%, ERIC -7.8%, BG -7.5%, ESI -7.4%, ADS -6.8%, SPAR -6.3%, NVEC -6.1%, EQIX -5.9% (also announced plan to acquire Switch and Data in a transaction valued at ~$689 million in cash and stock), AFFX -5.2%, CTXS -4.9%, MAC -4.4% (also proposed 12 mln share public offering of common stock), TSCO -3.8%, POT -3.4%, CNX -3.1%, ISIL -2.8%, QLGC -2.7%, EBAY -2.6%, AMGN -2.5%, WIRE -2.1%, CVD -1.4% (light volume), CS -1.3%... Select metals/mining names showing weakness: MT -1.8%, RTP -1.5%... Other news: RFMD -4.4% (ZTE has selected two of RFMD's dual-band transmit modules to support ZTE's S305 GSM handset), CMG -3.5% (announces proposal to convert class B stock into a single class of common stock), WTNY -1.0% (announces pricing of common stock offering of $8.00 per share)... Analyst comments: MWE -2.7% (downgraded to Mkt Perform at Wells Fargo), CHK -1.5% (downgraded to Neutral from Buy at UBS), AEE -1.4% (downgraded to Underweight from Neutral at JP Morgan), SAP -1.2% (downgraded to Neutral at BofA/Merrill), EOG -1.0% (downgraded to Neutral from Buy at UBS).